Meda AB

Meda AB was a leading international specialty pharmaceutical company headquartered in Solna, Sweden. It was founded in 1995 through the merger of several smaller pharmaceutical companies. Meda AB specialized in the acquisition and marketing of pharmaceuticals, with a focus on specialty products, over-the-counter (OTC) medications, and branded generics. The company's portfolio included a wide range of therapeutic areas such as respiratory, cardiology, pain and inflammation, dermatology, and central nervous system disorders.

History

Meda AB's history began in 1995, when it was established as a result of the merger of a number of smaller pharmaceutical entities. Over the years, Meda AB grew both organically and through a series of strategic acquisitions. Notable acquisitions included the purchase of the American company MedPointe and the European operations of Valeant Pharmaceuticals. These acquisitions helped Meda AB to significantly expand its product portfolio and geographical footprint.

Products

Meda AB's product line was diverse, covering several key therapeutic areas. The company was particularly known for its respiratory and allergy medications, such as Azelastine for allergic rhinitis, and Dymista, a combination nasal spray for the treatment of nasal symptoms. In the pain management sector, Meda AB marketed products like Naproxen, an anti-inflammatory drug. The company also had a strong presence in dermatology, with treatments for conditions such as psoriasis and eczema.

Acquisition by Mylan

In 2016, Meda AB was acquired by Mylan N.V., a global pharmaceutical company, in a deal valued at approximately $7.2 billion. This acquisition was part of Mylan's strategy to expand its portfolio of specialty and branded generic pharmaceuticals. Following the acquisition, Meda AB became a part of Mylan's global operations, contributing to its presence in over 165 countries and territories.

Corporate Social Responsibility

Meda AB was committed to corporate social responsibility (CSR), focusing on ethical business practices, environmental sustainability, and access to healthcare. The company aimed to reduce its environmental impact through efficient use of resources and sustainable manufacturing processes. Additionally, Meda AB participated in various initiatives to improve access to essential medications in developing countries.

Conclusion

Meda AB played a significant role in the international pharmaceutical industry, known for its diverse product portfolio and strategic acquisitions. The acquisition by Mylan N.V. marked the end of Meda AB as an independent entity but its legacy continues within the larger Mylan framework, contributing to the availability of quality healthcare products worldwide.